Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Oncolytics Biotech Inc. (USA)
ONCY | US
1.26
USD-0.09
-6.67%
ONCY | US
About Oncolytics Biotech Inc. (USA)
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.26
Open
1.36
High
1.37
Low
1.23
Oncolytics Biotech Inc. a development-stage biopharmaceutical company focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep an intravenously delivered immunotherapeutic agent which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary Canada.
View LessONCY | US
Risk
156.5
Sharpe
-0.47
Luna's Score
36/100
Recommendation
Sell
Luna says (ONCY | US)
What's Working
Positive Momentum
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
162.2%1 month
156.5%3 months
93.6%6 months
69.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
7.80
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-1.79
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-36.45M
MarketCap
96.84M
MarketCap(USD)
96.84M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-138.22
Short ratio
5.43
Short perc.
1.41
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.41
Range1M
0.69
Range3M
0.69
Volumes: Market Activity
Rel. volume
1.02
Price X volume
1.11M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.79 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.80 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 93.62 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 96.84M | 3.66B | Emerging |
